Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Oban BioPharma, Inc.
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism
June 5, 2026